Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real‐World Propensity Score‐Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup
Alimentary Pharmacology & Therapeutics · 2026-11 · 64 (10) · 1421-1431
DOI: 10.1111/apt.70954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 06.09.2026. Verfasst von Sara Massironi und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Stomach Neoplasms, Autoimmune Diseases, Neuroendocrine Tumors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
Background and Aims Autoimmune gastritis (AIG) is characterized by chronic hypergastrinemia and is associated with an increased risk of gastric neuroendocrine neoplasms (gNENs). Because proton pump inhibitors (PPIs) further increase gastrin secretion, concerns have been raised regarding a potential additive effect on gastric neoplastic risk. This study aimed to evaluate the association between PPI exposure and gNEN occurrence in patients with AIG using a large real‐world database.
Methods
We conducted a retrospective propensity score‐matched cohort study using the TriNetX Global Collaborative Network. Patients with AIG were identified using diagnostic codes for chronic atrophic gastritis or pernicious anaemia, excluding Helicobacter pylori infection, gastric cancer, multiple endocrine neoplasia or other competing gastric conditions. Two cohorts were defined: patients with AIG receiving PPIs and patients without PPI exposure. The primary outcome was the overall occurrence of gNENs. A prespecified secondary analysis excluded patients with gNENs diagnosed before the index date to evaluate incident tumours. Secondary outcomes included hypergastrinemia, intestinal metaplasia and gastric polyps.
Results
A total of 153,687 patients with AIG were identified. After 1:1 propensity score matching, 40,489 patients were included in each cohort. After propensity score matching, gNENs were recorded in 241 patients (0.60%) without PPI exposure and 360 patients (0.89%) receiving PPIs. PPI exposure was associated with a significantly higher occurrence of gNENs (risk ratio [RR] 1.49, 95% CI 1.27–1.76), which was confirmed by time‐to‐event analysis (hazard ratio [HR] 1.44, 95% CI 1.22–1.70; log‐rank p < 0.001). The association persisted after exclusion of patients with pre‐existing gNENs (RR 1.61, 95% CI 1.26–2.06; HR 1.52, 95% CI 1.19–1.95). PPI exposure was also associated with higher occurrences of hypergastrinemia (HR 1.17, 95% CI 1.00–1.37), intestinal metaplasia (HR 1.53, 95% CI 1.36–1.71) and gastric polyps (HR 2.48, 95% CI 2.25–2.73). No gastric adenocarcinomas were identified during follow‐up.
Conclusions
In this large real‐world propensity score‐matched study, PPI exposure was associated with a greater occurrence of both overall and incident gNENs in patients with AIG. PPI use was also consistently associated with gastric mucosal alterations, including hypergastrinemia, intestinal metaplasia and gastric polyps. Although the absolute risk of gNENs remained low, these findings support judicious long‐term PPI prescribing in patients with AIG and reinforce the importance of appropriate endoscopic surveillance in this high‐risk population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine and Surgery, Vita-Salute San Raffaele University, Milan, Italy.
- Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
- First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
- Department of Surgical-Medical Sciences and Translational Medicine, Digestive and Liver Disease Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.
- Gastroenterology and Endoscopy Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
- Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy.
ORCID-Profile: Sara Massironi, Marco Vincenzo Lenti, Edith Lahner, Chiara Della Bella, Federica Facciotti, Antonio Di Sabatino, Silvio Danese
Zitieren
APA
Massironi, S., Lenti, M. V., Lahner, E., Galbiati, M., Scatena, F., Miceli, E., Bella, C. D., Facciotti, F., D'Elios, M. M., Di Sabatino, A., Danese, S., & Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO) (2026). Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real‐World Propensity Score‐Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup. Alimentary Pharmacology & Therapeutics, 64(10), 1421-1431. https://doi.org/10.1111/apt.70954
Vancouver
Massironi S, Lenti MV, Lahner E, Galbiati M, Scatena F, Miceli E, et al. Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real‐World Propensity Score‐Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup. Alimentary Pharmacology & Therapeutics. 2026;64(10):1421-1431. doi:10.1111/apt.70954
BibTeX
@article{Massironi2026,
author = {Massironi, Sara and Lenti, Marco Vincenzo and Lahner, Edith and Galbiati, Maria and Scatena, Flavia and Miceli, Emanuela and Bella, Chiara Della and Facciotti, Federica and D'Elios, Mario M and Di Sabatino, Antonio and Danese, Silvio and Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO), Autoimmune gastRitis Italian netwOrk Study grOup (ARIOSO)},
title = {Association Between Proton Pump Inhibitor Use and Gastric Neuroendocrine Neoplasms in Autoimmune Gastritis: A Real‐World Propensity Score‐Matched Study From the Autoimmune gastRitis Italian netwOrk Study grOup},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {10},
pages = {1421--1431},
doi = {10.1111/apt.70954}
}
EUVIMED